Expansion and Collaboration
In September 2006, the privately-owned GeoVax Inc. merged with Dauphin Technology Inc., a publicly traded company based in Schaumburg IL., which subsequently changed its name to GeoVax Labs Inc. GeoVax remained a subsidiary of GeoVax Labs. In a press release about the merger, it was noted that Atlanta's Emory University was the largest shareholder of GeoVax Labs, owning approximately 31% of its outstanding capital stock after the merger. CEO Mr. Donald Hildebrand was quoted as saying "Emory has supported the Company's efforts by providing original investment capital, AIDS vaccine patent filings and has exclusively licensed Dr. H. Robinson's original AIDS vaccine technology to GeoVax." However, the reverse merger was proposed as "the quickest and most viable method to finance our (GeoVax's) anticipated Phase 1 and 2 clinical trials."
The Future of GeoVax
According to Mr. Hildebrand, the long term goals of the company include collaborative or license agreements with major vaccine production companies, for development and manufacturing of the HIV vaccine, once regulatory approval is obtained. It is estimated that the global market for an AIDS vaccine is in the billions of dollars. The Company's common stock is quoted on the NASDAQ OTCBB under the symbol GOVX.OB.
